| INTRODUCTION
Diabetes during pregnancy is associated with increased risk of complications for both mother and child. Hyperglycaemia is present in approximately 7% of all pregnancies, either pre-existing (diabetes mellitus type 1 [DM1] or type 2 [DM2]) or as a result of gestational diabetes mellitus (GDM).
1 Optimizing glycaemic control is key in prenatal care
for diabetic women and is conventionally monitored by daily self monitoring of blood glucose (SMBG) and periodic assessment of HbA1c.
Unfortunately, despite strict target values for glucose and HbA1c, adverse pregnancy outcomes such as pre-eclampsia, caesarean section, high birth weight (macrosomia), shoulder dystocia and perinatal mortality, occur more often in women with diabetic pregnancies as compared to the general population. [2] [3] [4] Rates of macrosomia have been reported to be as high as 62.5% in neonates from women with diabetes. [5] [6] [7] Macrosomia increases the risk of stillbirth, obstructed labour, birth trauma and neonatal hypoglycaemia. 8, 9 Moreover, macrosomic children show long-term effects such as obesity and DM2. [10] [11] [12] A continuous glucose monitor (CGM) is a currently used tool that provides detailed insight into daily glucose fluctuations and individual glucose patterns. CGM use is advised for DM1 patients outside pregnancy under specific conditions. 13 . 15 No improvement was found in the rate of macrosomia (45% vs 35%; OR, 1.51; 95% CI, 0.79-2.91) and glycaemic control was similar throughout pregnancy. Both studies were well designed but were small, single-or two-centre, and focused on women with pregestational diabetes. Based on a systematic review, including the studies of Murphy and Secher, we previously concluded that there is a need for a larger RCT to clarify the possible benefit of using intermittent CGM during diabetic pregnancy. 16 We therefore conducted the Glucose Monitoring with Sensor 
| MATERIAL AND METHODS

| Study design
We performed an open label, multicentre, pragmatic, randomized controlled trial comparing standard care with additional use of CGM to standard treatment. The study was performed in 22 hospitals (univer- 
| Randomization and masking
Randomization was performed at each centre by a web-based computerized program using 1:1 randomization, stratified according to type of diabetes. Women and clinical staff were not blinded for treatment allocation.
| Procedures
Women allocated to CGM were instructed to use the device for 5-7 days every 6 weeks. Glucose profiles were obtained retrospectively, directly after each use, and were evaluated by the local endocri- All participating women in both intervention and control groups performed SMBG (4-8 times/day; at least fasting, after every meal, at bedtime and, preferably, also before every meal). They were provided with specific targets: 3.5-5.3 mmol/L for fasting state; ≤ 7.8 mmol/L 1 hour after meals; ≤ 6.7 mmol/L 2 hours after meals. HbA1c-levels were measured every 4 weeks throughout pregnancy. Additional obstetric and diabetes care was provided according to local protocols and national guidelines. Medical data were collected with the use of a web-based case report form hosted by an independent data manager.
| Study outcome measures
The primary outcome was macrosomia, defined as birth weight above the 90th centile for the Dutch population, adjusted for infant sex and gestational age. 18 Secondary maternal endpoints were pregnancyinduced hypertension, defined as systolic blood pressure ≥ 140 mm 
| Statistical analysis
The study was powered to detect a reduction in macrosomia from 45% to 30%, anticipated to outweigh the cost of CGM use. Taking into account a possible 10% protocol violation and drop-out rate, we needed a total of 300 women (150 in both arms) (Alpha-error, .05;
Beta-error, .20; one-sided test).
Outcome measurements were compared using the Chi square 
| RESULTS
Between July 2011 and September 2015, we enrolled 300 pregnant women with DM1 (n = 109), DM2 (n = 82) or GDM (n = 109) who were randomly assigned to either CGM (n = 147) or standard treatment (n = 153). One woman was lost to follow-up because she transfered to a non-participating hospital, while 4 women withdrew consent and 5 had a miscarriage after randomization. Thus, outcome data were available for 143 women in the CGM group and 147 women in the standard treatment group. The trial profile is represented in Figure 1 . Baseline characteristics, which were evenly distributed by randomization, are shown in Table 1 .
A total of 7 women with DM1 switched to RT CGM, 4 women from the intervention group and 3 from the control group. Furthermore, 44 women from the CGM group refused to (further) comply with the study protocol. Reasons for this included high burden of the study intervention (n = 8), discomfort of the device (n = 3) and reason for non compliance not specified (n = 33). Thus, 95 (66%) women from the CGM group and 144 (98%) women from the standard control group were included in the per-protocol analyses. A typical CGM read-out is given in Figure 2 . Mean gestational age at delivery was comparable in both groups.
Mean birth weight differed, but was not statistically significant (3355 g vs 3423 g; mean difference, 72; 95% CI, -226-82). Additionally, no difference was observed in the rate of extremely LGA or SGA.
Other foetal outcomes were comparable in both groups. Subgroup analyses for type of diabetes showed no significant difference in rate of macrosomia for DM1, DM2 and GDM (Table 3) . The possible protective effect of CGM on pregnancy-induced hypertension, pre-eclampsia and HELLP seemed restricted to women with DM1 ( Table 4) . Results of the per-protocol analysis for macrosomia were 32.6% vs 28.5% (RR, 1.15; 95% CI, 0.78-1.69). Maternal and foetal outcomes did not differ significantly when analysed per protocol.
Incidence of pre-eclampsia in the per protocol analysis was 4.2% vs 11.1% (P = .06) the number of cases with HELLP syndrome was 0 vs 4 (P = .10).
Outcome measures from the compliant (per protocol) women in the CGM group were not significantly different from those of the non-compliant women in the CGM group.
| DISCUSSION
In this multicentre, randomized, controlled trial we showed that intermittent use of retrospective CGM did not reduce the risk of macrosomia in women with DM1, DM2 or GDM requiring insulin therapy. were all randomized for CGM were included in the study by Murphy et al. As twin pregnancies are clearly distinctive in terms of foetal growth, as well as in terms of perinatal outcomes, they were excluded from our study. The incidence of macrosomia in Murphy's CGM group was 35%, which is almost identical to our findings (31%). These numbers are also comparable to other reported incidences of macrosomia, as opposed to 60% in the control group, which is a strikingly high number. Another noticeable result is that 11% of the CGM group involved a baby born SGA, as opposed to none in the control group. This might be a reflection of the twin pregnancies; nonetheless this is an unwanted result and it affects the birth weight analyses. Murphy et al. found a similar number of pre-eclampsia cases in both groups (2 vs 0 cases).
Our results confirm the results of the previous trial by Secher et al. 15 used intermittent RT-CGM and randomization was stratified according to type of diabetes. They found no difference in cases of pre-eclampsia (8% vs 9%). Maternal and foetal outcomes were similar, with the exception of a significantly lower incidence of pre-eclampsia in the CGM group, an effect that lost significance in the per protocol analysis and seemed restricted to DM1 and GDM patients. Glycaemic control, as measured by HbA1c levels, was similar in both groups. Differences in blood glucose variability and fluctuations are features of glycaemic control that we were not able to investigate in our study, SMBG alone (n = 107). There was a significant difference in large-forgestational-age infants, defined as birth weight > p90th, with 53% in the CGM group and 69% in the control group. Furthermore, a lower incidence of neonatal hypoglycaemia and fewer NICU admissions were seen in the CGM group. There was a small difference in HbA1c levels of −0.19%. 27 The positive results of this trial, as opposed to our negative findings, could be explained by the fact that CGM was used continuously. In addition, by using a run-in phase that excluded women who encountered technical or motivational difficulties, the study was designed to select a group of woman that was willing to actually use this tool. It must be noted that the rates of macrosomia reported in this trial are strikingly high, especially compared to the incidence of 35% that was reported in the initial trial by Murphy et al. 14 Our study has several strengths. First, our sample size is large,
providing enough power to demonstrate a possible effect of CGM use. Secondly, similar to the previous 2 RCTs concerning intermittent CGM use, our primary outcome measure is rate of macrosomia. Intervention during pregnancy represents an effort to ensure maternal or foetal benefits, and research should be powered by clinically relevant endpoints. Another strength of our study is the inclusion of all types of diabetes. So far, research concerning CGM focused on women with DM1 and DM2. However, the incidence of gestational diabetes is steeply rising and the line between DM2 and GDM is fading. GDM is considered to be an early stage of DM2, and often, women with latent DM2 are screened during pregnancy for the first time. Receiving a diagnosis of GDM, only after pregnancy are they shown to actually have DM2. This is, therefore, an interesting and relevant group to investigate. Our trial is the first RCT concernng use of CGM that includes women with insulin-treated gestational diabetes, apart from 1 prospective non-randomized cohort study from China that indicated possible improved outcomes. 23 Furthermore, the external validity of our trial, performed in 23 centres, is larger than that of the previous single-or 2-centre trials.
Our study also has some limitations. Enrolment took place over more than 4 years. Another limitation is the high number of patients that refused continued use of the CGM after the first or second time.
A total of 66% of our participants used CGM according to study pro- The results of our trial underline the importance of solid evaluation of an expensive technical tool before wide implementation. Continuous RT-CGM use, as opposed to intermittent use as assessed in trials so far, could be a further step in optimizing glucose control and pregnancy outcome, although continuous use is even more demanding for both patients and care providers. A small feasibility study concerning the use of closed loop therapy, combining CGM with an algorithm that determines the optimal amount of insulin delivered through a wearable insulin pump during pregnancy, suggests improved glucose control. 28 Regarding all interventions that aim to improve glycaemic control, it is important to reflect on the clinical benefit, especially during pregnancy when glucose control is an intermediate endpoint and improved pregnancy outcome is the ultimate goal in clinical practice. CGM registrations provide detailed information on glucose profiles and provide a valuable tool for education and research. In light of all the evidence that is now available, intermittent CGM use has no place in standard care for pregnant women with diabetes.
